glp-1 receptor agonist and dpp-4 inhibitor combination not recommended Frontiers | inhibitors for treating T2DM glp-1 receptor agonist and dpp-4
Description
For example, oral treatment with semaglutide for 68 weeks can lead to a weight loss of 17.4% in patients, with 89.2% of patients experiencing a weight loss of 5%
Like Novo Nordisks Ozempic and Wegovy, both of Eli Lillys tirzepatide drugs are injected on a weekly basis
Paratore S, Ciotti MT, Basille M, Vaudry D, Gentile A, Parenti R, et al
Mammalian Sirt1: insights on its biological functions
In a 48-week, placebo-controlled phase-2 trial (338 participants) reported by Lilly, the highest dose achieved a mean weight reduction of 24.2% (about 57.8 lb) at the end of treatment
To find additional ways to save on GLP-1s, consider discussing your insurance coverage with your doctor
